Optimer Pharmaceuticals (OPTR) Tops Q4 EPS Views; Revs Heavy

March 7, 2012 5:50 PM EST
Optimer Pharmaceuticals (NASDAQ: OPTR) reported Q4 EPS of $0.28, $0.17 better than the analyst estimate of $0.11. Revenue for the quarter came in at $64.6 million versus the consensus estimate of $43.19 million.

For earnings history and earnings-related data on Optimer Pharmaceuticals (OPTR) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings